Over the past funding period Development Funds were allocated primarily in support of new faculty recruitment, pilot projects, and to a lesser extent development of new shared resources. Funds in this category in the CCSG were limited to approximately $200K per year due to budgetary constraints following the last re-competition. Developmental funds and AECC resources, in general, were targeted to address areas of concern identified at the last CCSG review and areas assigned high priority by the senior leadership based upon the outcome of the Center's internal and external review processes. Over the past funding period a total of $1.21M was allocated to Developmental Funds from the CCSG. Of this, 38% was allocated to New Investigator Support, 37% for Pilot Projects, and 25% for New Shared Resources. There will be considerable opportunities for AECC faculty recruitment and pilot project funding that will accompany the opening of the new Michael F. Price Center for Genetic and Translational Medicine over the next funding period. There are developing shared resources that will be targeted for Developmental funds. It is anticipated that 40% of Developmental Funds will be utilized for faculty recruitment, 40% for pilot projects, and 20% for new shared resources. In this application $250,000 is requested in year one for Developmental Funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013330-38
Application #
8113373
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
38
Fiscal Year
2010
Total Cost
$365,464
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Agalliu, Ilir; Chen, Zigui; Wang, Tao et al. (2018) Oral Alpha, Beta, and Gamma HPV Types and Risk of Incident Esophageal Cancer. Cancer Epidemiol Biomarkers Prev 27:1168-1175
Bhargava, Ragini; Sandhu, Manbir; Muk, Sanychen et al. (2018) C-NHEJ without indels is robust and requires synergistic function of distinct XLF domains. Nat Commun 9:2484
Collu, Giovanna M; Jenny, Andreas; Gaengel, Konstantin et al. (2018) Prickle is phosphorylated by Nemo and targeted for degradation to maintain Prickle/Spiny-legs isoform balance during planar cell polarity establishment. PLoS Genet 14:e1007391
Doyle, Christopher R; Moon, Jee-Young; Daily, Johanna P et al. (2018) A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice. Infect Immun 86:
Anayannis, Nicole V; Schlecht, Nicolas F; Ben-Dayan, Miriam et al. (2018) Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. PLoS One 13:e0191581
Stepankova, Martina; Bartonkova, Iveta; Jiskrova, Eva et al. (2018) Methylindoles and Methoxyindoles are Agonists and Antagonists of Human Aryl Hydrocarbon Receptor. Mol Pharmacol 93:631-644
Maggi, Elaine C; Gravina, Silvia; Cheng, Haiying et al. (2018) Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model. Front Genet 9:6
Ingram, Jessica R; Blomberg, Olga S; Rashidian, Mohammad et al. (2018) Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A 115:3912-3917
Dulyaninova, Natalya G; Ruiz, Penelope D; Gamble, Matthew J et al. (2018) S100A4 regulates macrophage invasion by distinct myosin-dependent and myosin-independent mechanisms. Mol Biol Cell 29:632-642
Chen, Zigui; Schiffman, Mark; Herrero, Rolando et al. (2018) Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology 516:86-101

Showing the most recent 10 out of 1508 publications